On 24 February 2026, Everest Medicines (1952) held its Extraordinary General Meeting in a virtual format. Four ordinary resolutions were voted on by poll, with all passing by a clear majority.

Resolution 1, concerning the approval and ratification of a Commercialization Service Agreement, received 55.14 million votes in favor (99.88%) and 0.07 million against (0.12%). Resolution 2, regarding the grant of 0.53 million awards under the Pre-IPO ESOP, was approved by 129.44 million votes in favor (92.44%) and 10.58 million against (7.56%).

Resolution 3, involving the 2026 Share Scheme, obtained 129.71 million votes in favor (92.69%) and 10.23 million against (7.31%). Resolution 4, concerning the Service Provider Sublimit under the 2026 Share Scheme, passed with 129.83 million votes in favor (92.73%) and 10.18 million against (7.27%).

As of the date of the meeting, the total number of shares in issue was 353.58 million, with 2.10 million held by trustees for share schemes. Several shareholders, including those with allocations under the Company’s share schemes, were required to abstain from voting on relevant resolutions. All resolutions were duly approved as ordinary resolutions.